The role of pharmacomechanical endovascular intervention for iliofemoral vein thrombosis compared to conventional anticoagulation therapy

In Sub Kim, Won-Min Jo

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Although anticoagulation therapy is the primary treatment for deep vein thrombosis (DVT), it has not been associated with the rapid recanalization of the venous occlusion. Moreover, it is associated with long-term disability due to post-thrombotic syndrome (PTS). In contrast, pharmacomechanical endovascular intervention (PMI) results in more rapid clinical improvement in DVT patients, but there are few reports on its long-term outcomes. This retrospective study evaluated the clinical effectiveness of PMI compared to conventional anticoagulation therapy (ACA) for acute and subacute iliofemoral DVT. We reviewed the medical records of 102 patients with iliofemoral DVT. A total of 46 patients for ACA and 56 patients for PMI were enrolled. We analyzed the clinical differences between the PMI and ACA groups by comparing the clinical signs, residual DVT free-rate, and PTS-free rate. There were no statistically significant differences in the demographic characteristics and risk factors except age between the groups (age: ACA, 52.0 ± 18.0 years; PMI, 59.0 ± 17.0 years; P=0.035). The 1-, 3-, and 5-year residual DVT-free rate (ACA=84.7%, 71.6%, and 46.0%; PMI=82.1%, 76.8%, and 76.8%, respectively; P=0.235) was not significantly different. However, the 1-, 3-, and 5-year PTS-free rate was significantly different (ACA=93.5%, 74.0%, and 55.7%; PMI=92.9%, 90.0%, and 90.0%, respectively; P=0.019). There was no significant difference in the rate of other complications. PMI showed a lower incidence of PTS during the follow-up period. Therefore, PMI should be considered as an effective therapeutic modality for patients with iliofemoral DVT.

Original languageEnglish
Pages (from-to)47-53
Number of pages7
JournalJournal of Korean Medical Science
Volume32
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Veins
Venous Thrombosis
Thrombosis
Therapeutics
Group Psychotherapy
Medical Records
Retrospective Studies
Age Groups
Demography
Incidence

Keywords

  • Deep vein thrombosis anticoagulants
  • Endovascular procedure
  • Post-thrombotic syndrome
  • Venous thrombosis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{01cfa62fd6c74218a9ec9cdd00d70fb5,
title = "The role of pharmacomechanical endovascular intervention for iliofemoral vein thrombosis compared to conventional anticoagulation therapy",
abstract = "Although anticoagulation therapy is the primary treatment for deep vein thrombosis (DVT), it has not been associated with the rapid recanalization of the venous occlusion. Moreover, it is associated with long-term disability due to post-thrombotic syndrome (PTS). In contrast, pharmacomechanical endovascular intervention (PMI) results in more rapid clinical improvement in DVT patients, but there are few reports on its long-term outcomes. This retrospective study evaluated the clinical effectiveness of PMI compared to conventional anticoagulation therapy (ACA) for acute and subacute iliofemoral DVT. We reviewed the medical records of 102 patients with iliofemoral DVT. A total of 46 patients for ACA and 56 patients for PMI were enrolled. We analyzed the clinical differences between the PMI and ACA groups by comparing the clinical signs, residual DVT free-rate, and PTS-free rate. There were no statistically significant differences in the demographic characteristics and risk factors except age between the groups (age: ACA, 52.0 ± 18.0 years; PMI, 59.0 ± 17.0 years; P=0.035). The 1-, 3-, and 5-year residual DVT-free rate (ACA=84.7{\%}, 71.6{\%}, and 46.0{\%}; PMI=82.1{\%}, 76.8{\%}, and 76.8{\%}, respectively; P=0.235) was not significantly different. However, the 1-, 3-, and 5-year PTS-free rate was significantly different (ACA=93.5{\%}, 74.0{\%}, and 55.7{\%}; PMI=92.9{\%}, 90.0{\%}, and 90.0{\%}, respectively; P=0.019). There was no significant difference in the rate of other complications. PMI showed a lower incidence of PTS during the follow-up period. Therefore, PMI should be considered as an effective therapeutic modality for patients with iliofemoral DVT.",
keywords = "Deep vein thrombosis anticoagulants, Endovascular procedure, Post-thrombotic syndrome, Venous thrombosis",
author = "Kim, {In Sub} and Won-Min Jo",
year = "2017",
month = "1",
day = "1",
doi = "10.3346/jkms.2017.32.1.47",
language = "English",
volume = "32",
pages = "47--53",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "1",

}

TY - JOUR

T1 - The role of pharmacomechanical endovascular intervention for iliofemoral vein thrombosis compared to conventional anticoagulation therapy

AU - Kim, In Sub

AU - Jo, Won-Min

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although anticoagulation therapy is the primary treatment for deep vein thrombosis (DVT), it has not been associated with the rapid recanalization of the venous occlusion. Moreover, it is associated with long-term disability due to post-thrombotic syndrome (PTS). In contrast, pharmacomechanical endovascular intervention (PMI) results in more rapid clinical improvement in DVT patients, but there are few reports on its long-term outcomes. This retrospective study evaluated the clinical effectiveness of PMI compared to conventional anticoagulation therapy (ACA) for acute and subacute iliofemoral DVT. We reviewed the medical records of 102 patients with iliofemoral DVT. A total of 46 patients for ACA and 56 patients for PMI were enrolled. We analyzed the clinical differences between the PMI and ACA groups by comparing the clinical signs, residual DVT free-rate, and PTS-free rate. There were no statistically significant differences in the demographic characteristics and risk factors except age between the groups (age: ACA, 52.0 ± 18.0 years; PMI, 59.0 ± 17.0 years; P=0.035). The 1-, 3-, and 5-year residual DVT-free rate (ACA=84.7%, 71.6%, and 46.0%; PMI=82.1%, 76.8%, and 76.8%, respectively; P=0.235) was not significantly different. However, the 1-, 3-, and 5-year PTS-free rate was significantly different (ACA=93.5%, 74.0%, and 55.7%; PMI=92.9%, 90.0%, and 90.0%, respectively; P=0.019). There was no significant difference in the rate of other complications. PMI showed a lower incidence of PTS during the follow-up period. Therefore, PMI should be considered as an effective therapeutic modality for patients with iliofemoral DVT.

AB - Although anticoagulation therapy is the primary treatment for deep vein thrombosis (DVT), it has not been associated with the rapid recanalization of the venous occlusion. Moreover, it is associated with long-term disability due to post-thrombotic syndrome (PTS). In contrast, pharmacomechanical endovascular intervention (PMI) results in more rapid clinical improvement in DVT patients, but there are few reports on its long-term outcomes. This retrospective study evaluated the clinical effectiveness of PMI compared to conventional anticoagulation therapy (ACA) for acute and subacute iliofemoral DVT. We reviewed the medical records of 102 patients with iliofemoral DVT. A total of 46 patients for ACA and 56 patients for PMI were enrolled. We analyzed the clinical differences between the PMI and ACA groups by comparing the clinical signs, residual DVT free-rate, and PTS-free rate. There were no statistically significant differences in the demographic characteristics and risk factors except age between the groups (age: ACA, 52.0 ± 18.0 years; PMI, 59.0 ± 17.0 years; P=0.035). The 1-, 3-, and 5-year residual DVT-free rate (ACA=84.7%, 71.6%, and 46.0%; PMI=82.1%, 76.8%, and 76.8%, respectively; P=0.235) was not significantly different. However, the 1-, 3-, and 5-year PTS-free rate was significantly different (ACA=93.5%, 74.0%, and 55.7%; PMI=92.9%, 90.0%, and 90.0%, respectively; P=0.019). There was no significant difference in the rate of other complications. PMI showed a lower incidence of PTS during the follow-up period. Therefore, PMI should be considered as an effective therapeutic modality for patients with iliofemoral DVT.

KW - Deep vein thrombosis anticoagulants

KW - Endovascular procedure

KW - Post-thrombotic syndrome

KW - Venous thrombosis

UR - http://www.scopus.com/inward/record.url?scp=85008234724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008234724&partnerID=8YFLogxK

U2 - 10.3346/jkms.2017.32.1.47

DO - 10.3346/jkms.2017.32.1.47

M3 - Article

C2 - 27914131

AN - SCOPUS:85008234724

VL - 32

SP - 47

EP - 53

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 1

ER -